Research Projects & Grants

For Profit Organization

• A long-term, open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis (JIA), Role: Investigator, Pfizer Pharmaceuticals, (05/2022 - 05/2023) Status: Completed
• A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of Obinutuzumab in adolescent patients with active class III or IV Lupus Nephritis, Including an Evaluation of Open-Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to, Role: Investigator, Hoffmann-La Roche Inc., (12/2025 - 12/2026) Status: Approved
• An open-label, multicenter study to evaluate the pharmacokinetics, safety and tolerability up to 6 years of intravenous secukinumab infusions in pediatric participants with Juvenile Psoriatic Arthritis, Role: Investigator, Novartis Pharmaceuticals Corporation, (12/2025 - 12/2026) Status: Approved